tbuckley/cabot-search huggingface dataset:
Capacités des laboratoires pour identifier les virus d’origine alimentaire en Europe
Authors: B A Lopman, Y T H P van Duynhoven, F X Hanon, M Reacher, M Koopmans, D W Brown
Journal: Eurosurveillance (2002)

Cet article decrit une enquete sur les capacites nationales des laboratoires de diagnostic et sur les bases de donnees de surveillance des virus d’origine alimentaire, aupres du consortium europeen sur les  Foodborne viruses in Europe . 
Tous les pays ont des laboratoires pouvant rechercher les anticorps anti-VHA dans le serum humain. Huit des dix pays europeens etudies entretiennent une base de donnees nationale sur les cas de VHA. La nourriture peut etre analysee pour la presence du VHA en Finlande, en Italie, en Espagne, en France et au Danemark.
Tous les pays etudies ont au moins un laboratoire pour analyser le virus de Norwalk (VDN) par PCR inverse et microscopie electronique. Cinq pays maintiennent une base de donnees nationale sur les cas de VDN, et neuf autres ont une base de donnees nationale sur les epidemies de VDN. Presque tous les participants ont des laboratoires capables de detecter la presence du VDN dans les aliments tels que les fruits de mer.
Patient Reported Symptoms and Tryptase Levels in WHO-Defined Systemic Mastocytosis (SM) Versus Mast Cell Activation Syndrome (MCAS) Versus Neither
Authors: Darci Zblewski, Ramy A. Abdelrahman, Dong Chen, Joseph H. Butterfield, Ayalew Tefferi, Animesh Pardanani
Journal: Blood (2014)
A randomized phase II study of axitinib (AG-013736) and gemcitabine versus gemcitabine in advanced pancreatic cancer, preceded by a phase I component
Authors: J. Spano, C. Chodkiewicz, J. Maurel, R. P. Wong, H. S. Wasan, Y. K. Pithavala, P. W. Bycott, K. Liau, S. Kim, O. Rixe
Journal: Journal of Clinical Oncology (2007)

4551 Background: The current standard of care for patients (pts) with advanced pancreatic cancer (APC) is gemcitabine (GEM)- based chemotherapy. Axitinib (AG) is a potent inhibitor of vascular endothelial growth factor receptors. A phase I study of AG in solid tumors identified 5 mg BID as the therapeutic starting dose. The main objectives of this trial are to determine whether the overall survival (OS) of the combination of AG and GEM is superior to that of GEM alone as first-line therapy in pts with APC, and to determine doses of AG and GEM that can be safely administered together. Methods: 8 pts were treated on the phase 1 (P1) portion of this trial. For the phase 2 (P2) portion of the trial, 103 pts with locally advanced or metastatic disease, no prior GEM or VEGF/VEGFR inhibitors, PS 0–2 were randomized (2:1) to GEM 1,000 mg/m 2 over 30 minutes on days (D) 1, 8, 15 every 28 D with or without AG at a starting dose of 5 mg po BID between Jan 06 and Aug 06. CT scans were performed every 2 cycles. Results: Data from the evaluable P1 pts (n=5) indicated that PK of GEM and AG appeared to be unchanged in combination. The GEM mean plasma exposure (AUC) was 11,348 alone vs 12,840 ng.h/mL with AG; similarly mean steady-state AG AUC was 250 alone vs 270 ng.h/mL with GEM. 3 of 8 pts had a PR. The median number of days on study drug was 158 days (range: 57–330 days) with 2 pts ongoing. Data from the randomized P2 pts: male 48%; median age 62 (36- 81); PS 0/1 vs 2: 91% vs 9%; 41% with locally advanced disease; 59% with metastatic disease. The most commonly reported adverse events are anemia (48%), alk phos elevations (48%), leukopenia (45%), neutropenia (42%), LFT elevations (39%), and thrombocytopenia (27%). The most common non-hematologic adverse events are nausea (24%), vomiting (20%), fatigue (19%), diarrhea (18%), anorexia (18%), constipation (13%), dyspnea (12%), and pyrexia (12%). 55 events have been reported in the 103 P2 pts. The pooled median OS is 203 days with a 95% CI of (158, not estimable). The median follow-up time is currently 223 days. Conclusions: AG can be safely administered at a starting dose of 5 mg BID in combination with standard dose GEM in patients with APC. Final safety and OS results by treatment arm will be presented. [Table: see text]
Carfilzomib Platform Study Using The LAGκ-1A Multiple Myeloma Xenograft Model
Authors: Eric Sanchez, Mingjie Li, Suzie Vardanyan, Jillian Gottlieb, Kevin Delijani, Joseph Ben-Zvi, Mitchell Song, Ran Halleluyan, Cathy S Wang, Haiming Chen, James R. Berenson
Journal: Blood (2013)
Bidirectional intragraft alloreactivity drives the repopulation of human intestinal allografts and correlates with clinical outcome
Authors: Julien Zuber, Brittany Shonts, Sai-Ping Lau, Aleksandar Obradovic, Jianing Fu, Suxiao Yang, Marion Lambert, Shana Coley, Joshua Weiner, Joseph Thome, Susan DeWolf, Donna L. Farber, Yufeng Shen, Sophie Caillat-Zucman, Govind Bhagat, Adam Griesemer, Mercedes Martinez, Tomoaki Kato, Megan Sykes
Journal: Science Immunology (2016)

A paradigm in transplantation states that graft-infiltrating T cells are largely non-alloreactive "bystander" cells. However, the origin and specificity of allograft T cells over time has not been investigated in detail in animals or humans. Here, we use polychromatic flow cytometry and high throughput TCR sequencing of serial biopsies to show that gut-resident T cell turnover kinetics in human intestinal allografts are correlated with the balance between intra-graft host-vs-graft (HvG) and graft-vs-host (GvH) reactivities and with clinical outcomes. In the absence of rejection, donor T cells were enriched for GvH-reactive clones that persisted long-term in the graft. Early expansion of GvH clones in the graft correlated with rapid replacement of donor APCs by the recipient. Rejection was associated with transient infiltration by blood-like recipient CD28+ NKG2DHi CD8+ alpha beta T cells, marked predominance of HvG clones, and accelerated T cell turnover in the graft. Ultimately, these recipient T cells acquired a steady state tissue-resident phenotype, but regained CD28 expression during rejections. Increased ratios of GvH to HvG clones were seen in non-rejectors, potentially mitigating the constant threat of rejection posed by HvG clones persisting within the tissue-resident graft T cell population.
Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment
Authors: Yi Wang, Yao-Xin Lin, Sheng-Lin Qiao, Hong-Wei An, Yang Ma, Zeng-Ying Qiao, R.P. Yeshan J. Rajapaksha, Hao Wang
Journal: Biomaterials (2016)
Nilotinib Results in Improved Rates of Molecular Response in Turkish Newly Diagnosed CML-CP Patients: A 24-Month Update
Authors: Guray Saydam, Ibrahim Celalettin Haznedaroglu, Leylagul Kaynar, Akif S. Yavuz, Ridvan Ali, Birol Guvenc, Olga M. Akay, Zafer Baslar, Ugur Ozbek, Mehmet Sonmez, Demet Aydin, Mustafa Pehlivan, Bulent Undar, Simten Dagdas, Orhan M. Ayyildiz, Diyar Z. Akkaynak, Ilkiz M. Dag, Osman Ilhan
Journal: Blood (2014)
Linagliptin‐associated bullous pemphigoid that was most likely caused by IgG autoantibodies against the midportion of <scp>BP</scp> 180
Authors: A. Sakai, Y. Shimomura, O. Ansai, Y. Saito, K. Tomii, Y. Tsuchida, H. Iwata, H. Ujiie, H. Shimizu, R. Abe
Journal: British Journal of Dermatology (2016)

Bullous pemphigoid (BP) is a common autoimmune subepidermal blistering disease characterized by autoantibodies against BP180 and/or BP230, both of which are a major structural component of hemidesmosomes. In most cases, autoantibodies against NC16A domain of BP180 (BP180-NC16A) are detected, and as such the pathomechanisms of BP have been becoming clear.1 However, the initial triggers of the disease are still largely unidentified. Nevertheless, it has been shown that certain medications including antibiotics, neuroleptics, and NSAIDs can be associated with the development of BP.2 Recently, dipeptidyl peptidase-4 inhibitors (DPP-4i), also known as gliptins, a newly introduced oral medication for type 2 diabetes mellitus (T2DM), have been paid the most attention as a potent trigger of BP.

This article is protected by copyright. All rights reserved.
N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM).
Authors: R. S. Dronca, D. G. Perez, J. Allred, W. J. Maples, E. T. Creagan, B. A. Pockaj, J. S. Kaur, T. D. Moore, B. T. Marchello, S. Markovic
Journal: Journal of Clinical Oncology (2010)

8572 Background: A recently described escape mechanism of melanoma cells exposed to alkylating agents is the production of the pro-survival cytokine vascular endothelial growth factor (VEGF). We hypothesized that the combination of TMZ and RAD001 could provide an additive therapeutic benefit in metastatic melanoma and impact the antitumor immune response due to the effect of both agents on immune cell function. Methods: We conducted a single arm phase II trial of the combination of RAD001 (10 mg/day for 5 of 7 days) and TMZ (200 mg/m2 days 1-5 every 28 days) in patients with stage IV unresectable MM. Patients (pts) began therapy with RAD001 1 week before initiation of TMZ (cycle 1 = 5 weeks, other cycles = 4 weeks). Pts previously treated with systemic therapy (excluding study agents) were eligible. Major exclusion criteria were active brain metastases, abnormal liver/renal function, and poor performance status (PS > 2). The primary end point was 9 week progression free survival (PFS9) rate. With a sample size of 39, the one-stage study design had a significance level of 0.10 and 90% power to test the hypothesis that the true PFS9 rate is at most 35% vs the alternative of at least 55%. Regimen is considered promising if > 17 patients were PFS9 successes. Secondary end points included therapy associated changes of biomarkers of angiogenesis and immunity. Results: The study accrued 49 pts (1 ineligible) from 01/08-10/08 (median age: 60 years [range 28-84]). The most common metastatic sites were lungs (43%) followed by lymph nodes (28%) and liver (20%), with 27% of patients having prior chemotherapy. Of the first 39 evaluable pts, 17 (44%, 95% CI: 28-60%) were PFS9 successes. Overall 4 of 48 (8%) pts achieved a partial response, the median PFS was 2.4 months (95% CI: 2.1–4.0), and the median OS was 8.6 mos (95% CI: 7.1-12.2). Treatment was well tolerated, only 1 pt discontinued therapy due to toxicity (hyperlipidemia). Results of correlative laboratory studies are forthcoming. Conclusions: The combination of TMZ and RAD001 did not appear to offer a therapeutic advantage over TMZ-alone historic controls. Pending biomarker analysis may offer insights into potential combinations of the current regimen with other treatments in advanced melanoma. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis
Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site
Authors: Karin A. van Schie, Simone Kruithof, Pauline A. van Schouwenburg, Anke Vennegoor, Joep Killestein, Gertjan Wolbink, Theo Rispens
Journal: Journal of Allergy and Clinical Immunology (2016)
The selective social learner as an agent of cultural group selection
Authors: Sarah Suárez, Melissa Koenig
Journal: Behavioral and Brain Sciences (2016)

Abstract Developmental research characterizes even the youngest learners as critical and selective, capable of preserving or culling cultural information on the bases of informant accuracy, reasoning, or coherence. We suggest that Richerson et al. adjust their account of social learning in cultural group selection (CGS) by taking into consideration the role of the selective learner in the cultural inheritance system.
Hyaluronic Acid and Its Derivatives in Coating and Delivery Systems: Applications in Tissue Engineering, Regenerative Medicine and Immunomodulation
Authors: Helena Knopf‐Marques, Martin Pravda, Lucie Wolfova, Vladimir Velebny, Pierre Schaaf, Nihal Engin Vrana, Philippe Lavalle
Journal: Advanced Healthcare Materials (2016)

As an Extracellular Matrix (ECM) component, Hyaluronic acid (HA) plays a multi‐faceted role in cell migration, proliferation and differentiation at micro level and system level events such as tissue water homeostasis. Among its biological functions, it is known to interact with cytokines and contribute to their retention in ECM microenvironment. In addition to its biological functions, it has advantageous physical properties which result in the industrial endeavors in the synthesis and extraction of HA for variety of applications ranging from medical to cosmetic. Recently, HA and its derivatives have been the focus of active research for applications in biomedical device coatings, drug delivery systems and in the form of scaffolds or cell‐laden hydrogels for tissue engineering. A specific reason for the increase in use of HA based structures is their immunomodulatory and regeneration inducing capacities. In this context, this article reviews recent literature on modulation of the implantable biomaterial microenvironment by systems based on HA and its derivatives, particularly hydrogels and microscale coatings that are able to deliver cytokines in order to reduce the adverse immune reactions and promote tissue healing.
The cyclin dependent kinase 2 inhibitor downregulates interleukin 1-beta mediated induction of cyclooxygenase 2 expression in human lung carcinoma cells
Authors: Partha Mukhopadhyay, M. Aktar Ali, Peter Carreon, Animesh Nandi, Debabrata Saha
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

4917 

Purpose: To establish a correlation between cell cycle regulatory events and COX-2 induction that could potentially represent an attractive target for tumor-specific blockage of COX-2. In this study, we examined the effect of a potent inhibitor of CDK2 (BMS-387032) on cytokine-induced COX-2 expression in non small cell lung carcinoma cell lines. Methods: Immunoblot analysis for COX-1, COX-2 and CDK2 detection. Immunoprecipitation and immune complex kinase assay for CDK2 activity. RNase protection assays for COX-2 mRNA detection. Enzyme linked immuno-assays for prostaglandin analysis (PGE2). Luciferase assays to analyze the COX-2 promoter activity. Gelshift assays to identify the transcription factors that regulate COX-2 expression and siRNA analysis. Results: In this study, we furnish several lines of evidences that demonstrate a functional role for the CDK2 in interleukin 1β (IL-1β) induced COX-2 expression in H358 human NSCLC line by blocking CDK2 activity. First, we show that BMS-387032, a potent CDK2 inhibitor, blocks IL-1β induced expression as well as steady state mRNA levels of COX-2. Second, we demonstrate that siRNA that abrogates CDK2 expression also blocks IL-1β induced COX-2 expression. Third, results from in vitro kinase assays clearly demonstrate that IL-1β induces CDK2 activity in H358 cells and this activity is significantly inhibited by BMS-387032. Moreover, CDK2 inhibition blocks IL-1β induced binding to the NF-IL6 element of the COX-2 promoter and inhibits transcription of the cox-2 gene. We also observed that BMS-387032 does not inhibit the endogenous expression of COX-2 or prostaglandin synthesis in lung carcinoma cells. Finally, we provide evidence demonstrating that IL-1β induced signaling events such as p38 MAPK, p-SAPK/JNK, p-AKT and p-ERK 1, 2 are not inhibited by CDK2 inhibitor. Conclusion: Taken together, the data suggest that CDK2 activity may play an important event in the IL-1β induced COX-2 expression and PGE2 synthesis. We observed that IL-1β induced COX-2 expression is coupled to CDK2 in dividing tumor cells uncovers a new dimension in strategies directed towards tumor specific COX-2 inhibition and makes the cyclin dependent kinase-2 a potential target for therapeutic intervention in NSCLC.
Chd8 mediates cortical neurogenesis via transcriptional regulation of cell cycle and Wnt signaling
Authors: Omer Durak, Fan Gao, Yea Jin Kaeser-Woo, Richard Rueda, Anthony J Martorell, Alexi Nott, Carol Y Liu, L Ashley Watson, Li-Huei Tsai
Journal: Nature Neuroscience (2016)
Manifesto for a healthy and health-creating society
Authors: Nigel Crisp, David Stuckler, Richard Horton, Victor Adebowale, Sue Bailey, Maureen Baker, John Bell, John Bird, Carol Black, Jane Campbell, Janet Davies, Heather Henry, Robert Lechler, Andrew Mawson, Patrick H Maxwell, Martin McKee, Cathy Warwick
Journal: The Lancet (2016)
Final Results of a Phase 1 Study of 18F-FLT Positron Emission Tomography (PET)/Computed Tomography Imaging in Myelofibrosis (FLT-MF-2009 Study)
Authors: Annalisa Andreoli, Laetitia Vercellino, Matthieu John Ouvrier, Emmanuelle Barré, Bruno Cassinat, Virginie de Beco, Pascal Merlet, Christine Dosquet, Christine Chomienne, Sylvie Chevret, Marie-Elisabeth Toubert, Jean-Jacques Kiladjian
Journal: Blood (2014)
Misleading headlines muddy the water
Authors: R Gilbert, P Tookey
Journal: BMJ (2004)

The headline ‘Giving birth in water’ referring to the randomised controlled trial by Cluett et al(1) of water immersion versus augmentation for dystocia in labour, fuels the confusion about labour and delivery in water. This and other studies provide good evidence for the benefits of immersion in water during labour(2). But contrary to the BMJ headline, this study is not about the risks or benefits of delivery in water. Cluett et al reported a mean delay of 6 hours (range 2-10) between women leaving the pool and birth. We conducted a national surveillance study of deliveries in water and the results were compatible with there being a small overall increase or decrease in perinatal mortality among babies delivered in water(3). We concluded that perinatal mortality was not substantially higher among these infants than among those delivered conventionally. However, we, like others (4) did raise the possibility of specific harms, particularly for water aspiration and blood loss due to snapped umbilical cord. How should clinicians advise women wishing to deliver in water? The trial that needs to be done is to randomise women who labour in water, to pulling the plug (or getting out of the bath), versus remaining immersed for the second stage of labour. This may be difficult since women are likely to have strong preferences one way or the other!
An early innate response underlies severe influenza‐induced exacerbations of asthma in a novel steroid‐insensitive and anti‐<scp>IL</scp>‐5‐responsive mouse model
Authors: L. Ravanetti, A. Dijkhuis, Y. S. Sabogal Pineros, S. M. Bal, B. S. Dierdorp, T. Dekker, A. Logiantara, I. M. Adcock, N. L. Rao, L. Boon, G. Villetti, P. J. Sterk, F. Facchinetti, R. Lutter
Journal: Allergy (2016)

Acute worsening of asthma symptoms (exacerbation) is predominantly triggered by respiratory viruses, with influenza causing the most severe exacerbations. The lack of an adequate animal model hampers mechanistic insight and the development of new therapeutics.We developed and characterized a robust, consistent, and reproducible mouse model of severe exacerbation of chronic allergic asthma.Chronic allergic airway inflammation was induced following a house dust mite (HDM) sensitization protocol. HDM-sensitized mice and controls were infected with influenza virus A/X31 H3N2 and either or not treated with inhaled fluticasone propionate (FP), systemic corticosteroids (Pred), or anti-IL-5. Mice were killed at different time points after infection: Cellular accumulation and cytokines levels in the airways, PenH as a measure of airway hyper-responsiveness (AHR), and lung histology and viral replication were assessed.Infection with low-dose A/X31 H3N2 led to prolonged deterioration of lung function, aggravated mucus production, peri-vascular, peri-bronchial, and allergic inflammation that was unresponsive to inhaled corticosteroids, but responsive to systemic corticosteroids. The exacerbation was preceded at 14 h after virus exposure by a marked innate, but no Th2 and Th1 response subsequently followed by enhanced numbers of eosinophils, neutrophils, dendritic, and T cells into the lung lumen, parenchyma, and draining lymph nodes in HDM-sensitized mice. Anti-IL-5 treatment attenuated eosinophils and prevented the X31-induced exacerbation.Together, these findings indicate that an early innate response that involves eosinophils underlies the exacerbation. This model recapitulates all major features of severe asthma exacerbations and can serve to discern driving mechanisms and promote the development of novel therapeutics.
David Oliver: Hospitals are not the enemy
Authors: David Oliver
Journal: BMJ (2016)

Even as an acute hospital doctor I recently shouted at the television, when Newsnight reduced a debate on the whole NHS to one about hospitals,1 “There are other services, you know!” I understand why non-hospital staff are even more exasperated at the obsession with hospitals.

The health service’s internal commentariat repeatedly blames hospitals, and the frontline staff who work in them, for the NHS’s problems.2 3 4 We’re too financially dominant, apparently, and the government gives us too much priority. It argues that hospitals, in their current form, inhibit vital investment in primary and community services …
Compulsory licences for direct acting antiviral drugs for hepatitis C
Authors: Adriano Cattaneo, Gavino Maciocco
Journal: BMJ (2016)

In Italy, the decision to ration treatment with direct acting drugs against hepatitis C virus was taken behind closed doors by the Ministry of Health. A 12 week course of treatment with sofosbuvir costs €41 000 (£35 500; $46 000), and the ministry has so far authorised 55 000 treatments—about 5% of the estimated need. The reason …
Research of a novel biodegradable surgical staple made of high purity magnesium
Authors: Hongliu Wu, Changli Zhao, Jiahua Ni, Shaoxiang Zhang, Jingyi Liu, Jun Yan, Yigang Chen, Xiaonong Zhang
Journal: Bioactive Materials (2016)

Surgical staples made of pure titanium and titanium alloys are widely used in gastrointestinal anastomosis. However the Ti staple cannot be absorbed in human body and produce artifacts on computed tomography (CT) and other imaging examination, and cause the risk of incorrect diagnosis. The bioabsorbable staple made from polymers that can degrade in human body environment, is an alternative. In the present study, biodegradable high purity magnesium staples were developed for gastric anastomosis. U-shape staples with two different interior angles, namely original 90° and modified 100°, were designed. Finite element analysis (FEA) showed that the residual stress concentrated on the arc part when the original staple was closed to B-shape, while it concentrated on the feet for the modified staple after closure. The in vitro tests indicated that the arc part of the original staple ruptured firstly after 7 days immersion, whereas the modified one kept intact, demonstrating residual stress greatly affected the corrosion behavior of the HP-Mg staples. The in vivo implantation showed good biocompatibility of the modified Mg staples, without inflammatory reaction 9 weeks post-operation. The Mg staples kept good closure to the Anastomosis, no leaking and bleeding were found, and the staples exhibited no fracture or severe corrosion cracks during the degradation.